Education
About Us
Working with TipRanks
Follow Us
Beta Bionics, Inc. (BBNX)
NASDAQ:BBNX
BBNX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$8.89 - $26.66
Previous CloseN/A
VolumeN/A
Average Volume (3M)916.71K
Market Cap
$966.34M
Enterprise Value$389.82M
Total Cash (Recent Filing)$249.72M
Total Debt (Recent Filing)$6.69M
Price to Earnings (P/E)―
Beta1.48
Next Earnings
Nov 05, 2025EPS Estimate
-0.42Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.39
Shares Outstanding43,470,123
10 Day Avg. Volume633,472
30 Day Avg. Volume916,709
Financial Highlights & Ratios
PEG Ratio-0.79
Price to Book (P/B)1.98
Price to Sales (P/S)2.31
P/FCF Ratio-2.91
Enterprise Value/Market Cap0.40
Enterprise Value/Revenue5.00
Enterprise Value/Gross Profit9.26
Enterprise Value/Ebitda-6.24
Forecast
1Y Price Target
$24.50Price Target Upside16.50% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering6
Bulls Say, Bears Say
Bulls Say
Market PotentialBBNX is the farthest along in developing a pump with a fully-closed loop algorithm, which requires zero patient engagements and has potential to further unlock the big PCP market.
Pharmacy Channel GrowthBBNX's continued execution of its commercial strategy, particularly in pharmacy which continues to scale quicker than expected.
Product InnovationBBNX demonstrated its patch pump at the investor event, showing that the patch is fully operational and plans a broad launch once cleared and ready.
Bears Say
Market CompetitionRisks include the inability to gain market share against larger players and potential delays to patch timing.
Beta Bionics, Inc. News
BBNX FAQ
What was Beta Bionics, Inc.’s price range in the past 12 months?
Beta Bionics, Inc. lowest stock price was $8.89 and its highest was $26.66 in the past 12 months.
What is Beta Bionics, Inc.’s market cap?
Beta Bionics, Inc.’s market cap is $966.34M.
When is Beta Bionics, Inc.’s upcoming earnings report date?
Beta Bionics, Inc.’s upcoming earnings report date is Nov 05, 2025 which is in 24 days.
How were Beta Bionics, Inc.’s earnings last quarter?
Beta Bionics, Inc. released its earnings results on Jul 29, 2025. The company reported -$0.39 earnings per share for the quarter, beating the consensus estimate of -$0.459 by $0.069.
Is Beta Bionics, Inc. overvalued?
According to Wall Street analysts Beta Bionics, Inc.’s price is currently Undervalued.
Does Beta Bionics, Inc. pay dividends?
Beta Bionics, Inc. does not currently pay dividends.
What is Beta Bionics, Inc.’s EPS estimate?
Beta Bionics, Inc.’s EPS estimate is -0.42.
How many shares outstanding does Beta Bionics, Inc. have?
Beta Bionics, Inc. has 43,470,123 shares outstanding.
What happened to Beta Bionics, Inc.’s price movement after its last earnings report?
Beta Bionics, Inc. reported an EPS of -$0.39 in its last earnings report, beating expectations of -$0.459. Following the earnings report the stock price went up 14.325%.
Which hedge fund is a major shareholder of Beta Bionics, Inc.?
Currently, no hedge funds are holding shares in BBNX
Beta Bionics, Inc. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$24.50 (16.50% Upside)
$24.50 (16.50% Upside)
Hedge Fund Trend
Increased
By 934.6K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $146.6K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
35.99%
Trailing 12-Months
Company Description
Beta Bionics, Inc.
Beta Bionics, Inc. (BBNX) is a medical technology company focused on developing innovative solutions for diabetes management. The company specializes in designing and manufacturing bionic pancreas systems that automate blood sugar management for individuals with diabetes. Their flagship product, the iLet Bionic Pancreas, aims to simplify diabetes care by using advanced algorithms and artificial intelligence to automate insulin and glucagon delivery.
BBNX Company Deck
BBNX Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call presented several positive developments, including strong revenue growth, an increase in new patient starts, and an expanded presence in the pharmacy channel. However, there were concerns about increased operating expenses, a notable churn rate, and potential uncertainties from CMS proposals. Overall, the positive aspects outweigh the negative, reflecting a strong quarter and optimistic future guidance.View all BBNX earnings summariesBBNX Stock 12 Month Forecast
Average Price Target
$24.50
▲(16.50% Upside)
Technical Analysis
Labcorp Holdings
―
Tandem Diabetes Care
―
Envista Holdings
―
Sana Biotechnology
―
Fortrea Holdings Inc.
―
Ownership Overview
9.91% Insiders
7.81% Mutual Funds
72.06% Other Institutional Investors
7.45% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---